INTREPID POTASH INC (IPI) 26.0773 +0.03 (+0.1%)
26.0773 +0.03 (+0.1%)
US46121Y2019 - Common Stock
Fundamental Rating
We assign a fundamental rating of 7 out of 10 to IPI. IPI was compared to 123 industry peers in the Chemicals industry. IPI scores excellent points on both the profitability and health parts. This is a solid base for a good stock. A decent growth rate in combination with a cheap valuation! Better keep an eye on IPI. This could make IPI a good candidate for value investing.
Profitability
Profitability Rating
IPI has a Return On Assets of 9.09%. This is better than the industry average of 7.57%.
IPI's Profit Margin of 21.39% is amongst the best returns of the industry. IPI outperforms 86% of its industry peers. The industry average Profit Margin is 8.83%.
The Piotroski-F score of IPI is 8.00. This is a very strong score and indicates great health and profitability for IPI.
IPI's Return On Equity of 10.10% is worse than the rest of the industry. The industry average Return On Equity is 19.27%. 84% of the industry peers have a better Return On Equity.
VS Industry
ROA (9.09%) VS Industry: 61% outperformed.
0.23
624.60
ROE (10.1%) VS Industry: 16% outperformed.
0.26
237.19
Profit Margin (21.39%) VS Industry: 86% outperformed.
0.51
45.08
Valuation
Valuation Rating
With a Price/Earnings Ratio of 4.39, the valuation of IPI can be described as very cheap.
Compared to an average industry Price/Earning Ratio of 11.66, IPI is valued rather cheaply. On top of this IPI is cheaper than 87% of the companies listed in the same industry.
With a Forward Price/Earnings Ratio of 7.21, the valuation of IPI can be described as cheap.
IPI's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
When comparing the current price to the book value of IPI, it is valued rather cheaply. It is trading at 0.47 times its book value.
Compared to an average industry price book ratio of 1.82, IPI is valued rather cheaply. On top of this, IPI is cheaper than 91% of the companies listed in the same industry.
When comparing the Enterprise Value to EBITDA ratio of IPI to the average industry ratio of 8.98, IPI is valued rather cheaply. IPI is also cheaper than 92% of the companies listed in the same industry.
VS Industry
Price/Earnings (4.39) VS Industry: 87% outperformed.
178.57
1.99
Price/Book (0.47) VS Industry: 91% outperformed.
764.36
0.02
Enterprise Value/ EBITDA (2.23) VS Industry: 92% outperformed.
13,692.96
0.15
Growth
Growth Rating
The Earnings Per Share has grown by an impressive 212.63% over the past year.
The Earnings Per Share has been growing by 75.44% on average over the past 5 years. This is a very strong growth
Looking at the last year, IPI shows a very strong growth in Revenue. The Revenue has grown by 24.85%.
The Revenue has been growing by 13.67% on average over the past 5 years. This is quite good.
Based on estimates for the next 5 years, IPI will show a very negative growth in Earnings Per Share. The EPS will decrease by -49.44% on average per year.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
IPI is expected to show a very negative growth in Revenue. In the coming 5 years, the Revenue will decrease by -10.76% yearly.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | 75.44% | 212.63% | -39.13% | -49.44% | N/A | N/A |
| Revenue | 13.67% | 15.32% | 24.85% | -4.87% | -10.76% | N/A | N/A |
Health
Health Rating
A Current Ratio of 3.51 indicates that IPI has no problem at all paying its short term obligations.
When comparing the Current Ratio to an average industry Current Ratio of 2.02, IPI is better placed than the average industry peer to meet its short term obligations.
With a Debt to Equity ratio of 0.00, IPI is one of the better performing companies in its industry. It outperforms 88% of its industry peers.
An Altman-Z score of 3.74 indicates that IPI is not in any danger for bankruptcy at the moment.
IPI is in better financial health than average in its industry. Its Altman-Z score is much better than the industry average of 2.50.
The Piotroski-F score of IPI is 8.00. This is a very strong score and indicates great health and profitability for IPI.
A Quick Ratio of 1.16 indicates that IPI should not have too much problems paying its short term obligations.
The Quick Ratio is in line with the industry averages, which is at 1.32.
VS Industry
Debt/Equity (0) VS Industry: 88% outperformed.
53.61
0.00
Quick Ratio (1.16) VS Industry: 43% outperformed.
0.01
65.94
Current Ratio (3.51) VS Industry: 77% outperformed.
0.01
65.94
Altman-Z (3.74) VS Industry: 75% outperformed.
-529.46
146.70
Dividend
Dividend Rating
No dividends for IPI!.
INTREPID POTASH INC26.0773
NYSE:IPI (3/20/2023, 2:45:21 PM)+0.03 (+0.1%)
| GICS Sector | Materials | ||
| GICS IndustryGroup | Materials | ||
| GICS Industry | Chemicals | ||
| Earnings (Last) | 03-06 2023-03-06/amc | Earnings (Next) | 05-01 2023-05-01/amc |
| Inst Owners | 50.97% | Inst Owner Change | -12.01% |
| Ins Owners | 14.73% | Ins Owner Change | -0.58% |
| Market Cap | 338.29M | Analysts | 44 |
| Price Target | 35.19 (34.94%) | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Dividend Growth(5Y) | N/A | DP | 0% |
| Div Incr Years | N/A | Div Non Decr Years | N/A |
| Ex-Date | N/A | ||
| EPS beat(2) | N/A | Avg EPS beat(2) | -28.48% |
| Min EPS beat(2) | -44.7% | Max EPS beat(2) | -12.27% |
| EPS beat(4) | 1 | Avg EPS beat(4) | -12.12% |
| Min EPS beat(4) | -44.7% | Max EPS beat(4) | 17.8% |
| Revenue beat(2) | 1 | Avg Revenue beat(2) | 11.03% |
| Min Revenue beat(2) | -9.18% | Max Revenue beat(2) | 31.25% |
| Revenue beat(4) | 3 | Avg Revenue beat(4) | 9.59% |
| Min Revenue beat(4) | -9.18% | Max Revenue beat(4) | 31.25% |
| PT rev (1m) | 0% | PT rev (3m) | -11.54% |
| EPS NQ rev (1m) | 0% | EPS NQ rev (3m) | -42.62% |
| EPS NY rev (1m) | -25.16% | EPS NY rev (3m) | -25.16% |
| Revenue NQ rev (1m) | 0% | Revenue NQ rev (3m) | -13.79% |
| Revenue NY rev (1m) | -3.37% | Revenue NY rev (3m) | -3.37% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.39 | ||
| Fwd PE | 7.21 | ||
| P/S | 1 | ||
| P/FCF | 16.81 | ||
| P/OCF | 3.81 | ||
| P/B | 0.47 | ||
| P/tB | 0.49 | ||
| EV/EBITDA | 2.23 |
| EPS(TTM) | 5.94 | EY | 22.78% |
| EPS(NY) | 3.62 | Fwd EY | 13.87% |
| FCF(TTM) | 1.55 | FCFY | 5.95% |
| OCF(TTM) | 6.85 | OCFY | 26.26% |
| SpS | 26.02 | BVpS | 55.12 |
| TBVpS | 53.15 | PEG (NY) | N/A |
| PEG (5Y) | N/A | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.09% | ||
| ROE | 10.1% | ||
| ROIC | 10.33% | ||
| ROICexc | 10.68% | ||
| ROICexgc | 11.08% | ||
| OM | 30.49% | ||
| PM | 21.39% | ||
| GM | 41.89% |
| ROICexgc(3y) | N/A | ROICexcg growth 3Y | 60.38% |
| ROICexcg growth 5Y | N/A | ROICexc(3y) | N/A |
| ROICexc growth 3Y | 60.58% | ROICexc growth 5Y | N/A |
| OM growth 3Y | 58.35% | OM growth 5Y | N/A |
| PM growth 3Y | 51.28% | PM growth 5Y | N/A |
| GM growth 3Y | 28.45% | GM growth 5Y | 44.33% |
| F-Score | 8 | Asset Turnover | 0.43 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 196.09% | ||
| Profit Quality | 27.87% | ||
| Current Ratio | 3.51 | ||
| Quick Ratio | 1.16 | ||
| Altman-Z | 3.74 |
| F-Score | 8 | WACC | 8.91% |
| ROIC/WACC | 1.24 | Cap/Depr(3y) | 102.08% |
| Cap/Depr(5y) | 118.8% | Profit Quality(3y) | N/A |
| Profit Quality(5y) | N/A | ||
| EPS 1Y | 212.63% | EPS 3Y | 75.44% |
| EPS 5Y | N/A | EPS growth Q2Q | 38.33% |
| EPS Next Y | -39.13% | EPS Next 2Y | -49.44% |
| EPS Next 3Y | N/A | EPS Next 5Y | N/A |
| Revenue growth 1Y | 24.85% | Revenue growth 3Y | 15.32% |
| Revenue growth 5Y | 13.67% | Revenue growth Q2Q | -7.17% |
| Revenue Next Year | -4.87% | Revenue Next 2Y | -10.76% |
| Revenue Next 3Y | N/A | Revenue Next 5Y | N/A |
| EBIT growth 1Y | 245.8% | EBIT growth 3Y | 82.61% |
| EBIT growth 5Y | N/A | EBIT Next Year | -6.57% |
| EBIT Next 3Y | N/A | EBIT Next 5Y | N/A |
| FCF growth 1Y | -66.05% | FCF growth 3Y | N/A |
| FCF growth 5Y | 44.45% | OCF growth 1Y | 12.34% |
| OCF growth 3Y | 21.6% | OCF growth 5Y | 39.69% |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA